ABBOTT LABORATORIES (ABT) Cash flow
Market cap
$165.9B
P/E ratio
25.7x
| 2010/12 | 2011/12 | 2013/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Stock-based compensation | 387 | 383 | 262 | 292 | 310 | 406 | 477 | 519 | 546 | 640 | 685 | 644 | 673 | 664 |
| Cash from operations | 8,736 | 8,970 | 3,324 | 2,966 | 3,203 | 5,570 | 6,300 | 6,136 | 7,901 | 10,533 | 9,581 | 7,261 | 8,558 | 9,566 |
| Capital expenditures | -1,015 | -1,491 | -1,145 | -1,110 | -1,121 | -1,135 | -1,394 | -1,638 | -2,177 | -1,885 | -1,777 | -2,202 | -2,207 | -2,171 |
| Cash from investing | -12,188 | 261 | -3,929 | 406 | -248 | -9,618 | -1,356 | -1,815 | -2,215 | -2,008 | -1,740 | -3,133 | -2,338 | -2,422 |
| Payments for dividends | 2,671 | 2,938 | 882 | 1,443 | - | - | - | - | - | - | - | - | - | - |
| Repurchases of common stock | 867 | 77 | 1,605 | 2,237 | 522 | 117 | 238 | 718 | 403 | 2,299 | 3,795 | 1,227 | 1,295 | 893 |
| Proceeds from issuance of term debt, net | 4,000 | 1,000 | 9 | 2,485 | 14,934 | 6,742 | 4,009 | 1,842 | 1,281 | 4 | - | - | - | - |
| Repayments of term debt | 1,674 | 3,012 | 303 | 57 | 12 | 8,650 | 12,433 | 3,441 | 1,333 | 48 | - | - | - | - |
| Cash from financing | -1,088 | -6,023 | -6,696 | -2,236 | 11,147 | -5,281 | -10,391 | -4,289 | -2,779 | -5,494 | -7,636 | -7,091 | -5,404 | -6,309 |
| Free cash flow | ||||||||||||||
| FCF margin (%) |